Crossmark

Efficacy of bortezomib combined with Hyper-CVAD in adults with relapsed acute lymphoblastic leukemia or positive measurable residual disease; effect of bortezomib in leukemia

Crossref DOI link: https://doi.org/10.1007/s44313-024-00050-6

Published Online: 2025-01-14

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ramos Peñafiel, Christian Omar https://orcid.org/0000-0003-0957-9090
Pérez Sámano, Daniela https://orcid.org/0000-0002-5935-6832
Gallardo Rodríguez, Adán Germán https://orcid.org/0000-0002-0279-3126
Terreros Palacio, Camila https://orcid.org/0009-0008-3860-8229
Olarte Carrillo, Irma https://orcid.org/0000-0002-5374-0534
Martínez Murillo, Carlos https://orcid.org/0000-0002-9950-0472
Barranco Lampón, Gilberto https://orcid.org/0000-0002-2988-7544
Cabrera García, Álvaro https://orcid.org/0000-0001-8646-7709
Martínez Tovar, Adolfo https://orcid.org/0000-0002-5713-3731
License Information

Text and Data Mining valid from 2025-01-14

Version of Record valid from 2025-01-14
More Information

Article History

Received: 16 July 2024

Accepted: 4 December 2024

First Online: 14 January 2025

Declarations

:

: Written informed consent was obtained from all the participants. The Biosecurity, Ethics and Research Committee of “Hospital General de México “Dr. Eduardo Liceaga” approved the informed consent.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below